血CA125水平对预测晚期卵巢癌新辅助化疗后理想肿瘤细胞减灭术的意义

发布时间：2018-01-04 09:32

本文关键词：血CA125水平对预测晚期卵巢癌新辅助化疗后理想肿瘤细胞减灭术的意义　出处：《现代医院》2016年05期 　论文类型：期刊论文

【摘要】：目的探讨血CA125水平对晚期卵巢癌患者新辅助化疗后理想肿瘤细胞减灭术的预测作用。方法回顾性分析2009年1月~2015年2月新诊断的晚期卵巢癌患者110例的临床资料,根据新辅助化疗后结果分为理想肿瘤细胞减灭术组(OCR组)及不理想细胞减灭术组(SCR组)。分析两组新辅助化疗前、后及手术后血CA125水平的变化,及其对理想手术成功率的预测作用。结果 OCR组及SCR组化疗前CA125分别为(1 466.1±682.4)、(1 628.2±738.7)U/m L,两组比较无统计学差异(t=1.196 4,P=1.117 1),而手术前两组CA125分别为(98.4±51.2)、(138.5±68.6)U/m L,有统计学差异(t=3.433 8,P=0.000 4),手术后尽管SCR组CA125水平(85.6±42.1)U/m L高于OCR组(78.1±36.3)U/m L,但两组比较无统计学意义(t=0.9363,P=0.1756)。术前CA125100 U/m L者OCR组50例,占86.21%,而SCR组则为31例,占67.31%,两组比较有统计学意义(x~2=9.986 8,P=0.001 6)。铂类敏感及耐药患者手术前CA125≤35 U/m L者分别为24例和13例,各占38.10%和27.66%,而手术前CA12535 U/m L者分别为39例和34例,分别各占61.90%和72.34%,两者比较无统计学差异(x~2=1.313 2,P=0.251 8)。铂类敏感及耐药患者手术前CA125下降≥80%者分别为52、26例,各占82.54%和55.32%,而手术前CA125下降80%者分别为11、21例,各占17.46%和44.68%,两者比较有统计学差异(x~2=9.669 0,P=0.001 9)。结论以顺铂为基础的联合新辅助化疗用于晚期卵巢癌,可明显提高理想肿瘤细胞减灭术成功率,同时术前血CA125水平可在一定程度上预测理想肿瘤细胞减灭术成功率。
[Abstract]:Objective to investigate the predictive role of cytoreductive surgery on the ideal blood CA125 level in tumor cell reduction neoadjuvant chemotherapy for advanced ovarian cancer patients. Methods Retrospective analysis of clinical data of patients with advanced ovarian cancer and 110 cases of newly diagnosed ~2015 in February January 2009, according to the neoadjuvant chemotherapy were divided into cytoreductive surgery group (OCR group) and not the ideal cytoreductive surgery group (group SCR). Analysis of neoadjuvant chemotherapy in two groups before and after the change of blood CA125 level after surgery, and the predictive value on the success rate of surgery. The ideal results in the OCR group and SCR group CA125 before chemotherapy respectively (1466.1 + 682.4), (1628.2 + 738.7) U/m L, the two groups had no significant difference (t=1.196 4, P=1.117 1), and two CA125 respectively before surgery group (98.4 + 51.2), (138.5 + 68.6) U/m L, there was significant difference (t=3.433 8, P=0.000 4), although the level of CA125 after surgery in group SCR (85.6 + 42.1) U/m higher than L group OCR (78.1 + 36 .3 U/m L), but there was no significant difference between the two groups (t=0.9363, P=0.1756). The preoperative CA125100 U/m L OCR group of 50 cases, accounting for 86.21%, while in SCR group for 31 cases, accounted for 67.31% of the two groups was statistically significant (x~2=9.986 8, P=0.001 6). Platinum sensitive and resistant patients CA125 less than 35 U/m L were 24 cases and 13 cases, accounting for 38.10% and 27.66%, and CA12535 U/m L before surgery were 39 cases and 34 cases, respectively accounted for 61.90% and 72.34%, there was no difference in Statistics (x~2=1.313 2, P=0.251 8). Platinum sensitive and resistant patients before surgery CA125 dropped more than 80% were 52,26 cases, each accounted for 82.54% and 55.32%, and CA125 before operation respectively decreased 80% 11,21 cases, accounting for 17.46% and 44.68%, the difference was statistically significant (x~2=9.669 0, P=0.001 9). Conclusion based on cisplatin combined with neoadjuvant chemotherapy for advanced ovarian cancer, can improve the ideal tumor cells The success rate of the reduction and the preoperative blood CA125 level can be used to predict the success rate of the ideal tumor cell reduction to a certain extent.

【作者单位】：河北医科大学附属唐山工人医院;天津医科大学总医院;
【基金】：唐山市科技局科技支撑项目(编号:No.111302097b)
【分类号】：R737.31
【正文快照】： 卵巢癌是妇科恶性肿瘤中最重要的死亡原因,肿瘤细胞减灭术加顺铂为主的联合化疗已成为标准的卵巢癌治疗模式。而新辅助化疗作为晚期肿瘤治疗的新模式,近年来已为广大肿瘤工作者所推崇,已被用于晚期宫颈癌及乳腺癌等的治疗[1-3]。目前认为新辅助化疗具有提高晚期卵巢癌患者理想

【参考文献】